Antonio Llombart
Arnau de Vilanova Hospital · Arnau de Vilanova Hospital, Valencia, Spain · Arnau de Vilanova Hospital, Valencia (Spain)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
19
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers in breast cancer
18
PubMed author-name match
Trials
Studies that name Antonio Llombart as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:55 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06525675 · Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)MedSIR · completed · Metastatic Breast Cancer, Advanced Breast Cancer, Luminal Breast Cancer · principal investigator
- Ph3NCT06382948 · Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.MedSIR · recruiting · Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer · principal investigator
- Ph2NCT06172127 · PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast CancerMedSIR · active not recruiting · HER2-positive Breast Cancer · principal investigator
- Ph2NCT05810870 · PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With EribulinMedSIR · active not recruiting · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer · principal investigator
- Ph2NCT05708235 · A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC PopulationMedSIR · active not recruiting · Breast Cancer · principal investigator
- Ph2NCT05659563 · Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%MedSIR · completed · Breast Cancer, Breast Cancer, Early-Onset · principal investigator
- Ph2NCT04733118 · Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast CancerMedSIR · active not recruiting · Early Breast Cancer · principal investigator
- Ph2NCT04714619 · CB-103 Plus NSAI In Luminal Advanced Breast CancerMedSIR · terminated · Advanced Breast Cancer · principal investigator
- Ph2NCT04603183 · ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaLMedSIR · completed · Breast Cancer Metastatic · principal investigator
- Ph2NCT04464174 · Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast CancerMedSIR · completed · Triple Negative Breast Cancer · principal investigator
- Ph2NCT04408118 · First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBCMedSIR · completed · Metastatic Breast Cancer, Advanced Breast Cancer, Triple Negative Breast Cancer · principal investigator
- Ph2NCT04300790 · Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC PatientsMedSIR · completed · Breast Cancer · principal investigator
- Ph2NCT04240106 · Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)MedSIR · completed · Breast Cancer, Breast Cancer Metastatic · principal investigator
- Ph2NCT03819010 · Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -MedSIR · completed · Breast Cancer · principal investigator
- Ph2NCT03161353 · Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.MedSIR · active not recruiting · Breast Cancer · principal investigator
- N/ANCT02506816 · Preoperative Olaparib Endometrial Carcinoma Study (POLEN)MedSIR · completed · Endometrial Carcinoma · study chair
- Ph2NCT02491983 · Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast CancerMedSIR · completed · Metastatic Breast Cancer · principal investigator
- Ph2NCT02061085 · Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line TreatmentMedSIR · completed · Breast Neoplasm, Metastasis · principal investigator
- Ph2NCT01973660 · PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast CancerSOLTI Breast Cancer Research Group · completed · Breast Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 12:55 UTC. The ranking covers the 200 most relevant of 18 PubMed records, and a shared surname and initials can bring in a namesake. All 18 on PubMed
- Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.J Clin Oncol · 2008312 citationsRCR 7.0
- 280 citationsRCR 8.2
- A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.J Clin Oncol · 2007175 citationsRCR 3.5
- 166 citationsRCR 3.7
- Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.J Clin Oncol · 2012143 citationsRCR 3.5
- Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01).J Clin Oncol · 2020118 citationsRCR 4.1
- Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.Clin Breast Cancer · 2012113 citationsRCR 3.1
- Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.J Clin Oncol · 200990 citationsRCR 2.2
- Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.Ann Oncol · 201478 citationsRCR 2.4
- A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.Breast Cancer Res Treat · 201357 citationsRCR 1.4